Intelligence · Clinical Pipeline

Neurology & CNS · Phase II

Neurology & CNS programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
230

Quick answer

Neurology & CNS Phase II programs: NovaPharmaNews indexes 230 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 3 of 5

  1. MINOCIN 100 mg capsule rigide

    Zafatek

    Depression

    phase 2 small molecule active

    1 trial
  2. MK-1167

    Merck KGaA, Darmstadt, Germany

    Alzheimer Disease

    phase 2 small molecule active

    1 trial
  3. MK-2214

    Merck KGaA, Darmstadt, Germany

    Early Alzheimer's Disease

    phase 2 mab active

    1 trial
  4. MK-2214, Florquinitau F18, Placebo to MK-2214

    Merck Sharp and Dohme

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial
  5. ML-007C-MA

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial
  6. ML-007C-MA

    MapLight Therapeutics

    Psychosis Associated With Alzheimer's Disease

    phase 2 small molecule active

    2 trials
  7. MLC901

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 small molecule active

    1 trial
  8. Matched Placebo for test product Frexalimab, Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial
  9. Matched placebo for product, GADOBUTROL , SAR443820

    Sanofi-aventis Healthcare Pty Ltd

    Multiple sclerosis

    phase 2 small molecule active

    1 trial
  10. Matching Placebo tablets without active substance, BIIB122

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial
  11. Mebufotenin, Mebufotenin, Inhalation vapour, liquid, Mebufotenin

    Elan Pharma International

    Treatment-resistant depression (TRD)

    phase 2 small molecule active

    1 trial
  12. Melperone HCl

    Lundbeck Australia Pty Ltd

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial
  13. Mifepristone

    CORCEPT THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial
  14. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 small molecule active

    1 trial
  15. Morphine

    Hospital Authority, Hong Kong

    Respiratory Depression

    phase 2 small molecule active

    1 trial
  16. N-acetyl cysteine

    United Therapeutics Europe Ltd

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial
  17. N-acetylcysteine capsule

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial
  18. NBI-1117570

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial
  19. NBI-1117570, NBI-1117570, Placebo for nbi-1117570

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial
  20. NBI-5788

    NEUROCRINE BIOSCIENCES INC

    Multiple Sclerosis

    phase 2 small molecule completed

    1 trial
  21. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prodromal Schizophrenia

    phase 2 small molecule active

    1 trial
  22. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    2 trials
  23. NMDAE plus AIFA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial
  24. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial
  25. NeuroEPO

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson Disease

    phase 2 small molecule completed

    1 trial
  26. NurOwn (MSC-NTF cells)

    BRAINSTORM CELL THERAPEUTICS INC.

    Multiple Sclerosis, Chronic Progressive

    phase 2 mab completed

    1 trial
  27. OPC-34712

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 2 small molecule completed

    1 trial
  28. ORY-2001 Low dose

    BRIGHT MINDS BIOSCIENCES INC.

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial
  29. Obexelimab

    Zenas BioPharma

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial
  30. Ocrevus 300 mg concentrate for solution for infusion, CYTARABINE, CARMUSTINE, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, Tysabri 300 mg concentrate for solution for infusion, CARMUSTINE, ETOPOSIDE, CARMUSTINE, UBLITUXIMAB, MELPHALAN FLUFENAMIDE, FILGRASTIM, FILGRASTIM, CYTARABINE, CYTARABINE, CYCLOPHOSPHAMIDE, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, Kesimpta 20 mg solution for injection in pre-filled pen, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, CYTARABINE, LEMTRADA 12 mg concentrate for solution f

    Fondazione Telethon ETS

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule active

    1 trial
  31. Ocrevus, Ocrevus 920 mg solution for injection, Ocrevus, Ocrelizumab

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 2 small molecule active

    1 trial
  32. PCN-101

    Chongqing Precision Biotech Co., Ltd

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial
  33. PEG-liposomal prednisolone sodium phosphate

    Lakefront Biotherapeutics NV

    Acute Exacerbation of Remitting Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial
  34. PIPE-307 Dose A

    Contineum Therapeutics

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial
  35. PRENUMBRA

    Clinuvel Europe Limited

    Parkinson's Disease

    phase 2 small molecule active

    1 trial
  36. PROLEUKIN 18 millions U.I., poudre pour solution injectable, CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Alzheimer Disease

    phase 2 small molecule active

    1 trial
  37. Pepinemab

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial
  38. Perindopril

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial
  39. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial
  40. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial
  41. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial
  42. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial
  43. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial
  44. Pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 2 small molecule completed

    1 trial
  45. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial
  46. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Depression

    phase 2 small molecule terminated

    1 trial
  47. Placebo

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial
  48. Placebo

    Teva Pharma GmbH

    Primary Progressive Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns Phase II programs exist?

230 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs